Recruiting

Observational Study

Sponsor:

City of Hope Medical Center

Code:

NCT06388967

Conditions

Pancreatic Cancer

Pancreatic Carcinoma

Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Pancreatic Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

PANcreatic cancer Exosome Early detectiON (PANXEON)

Study Details

Brief summary:

This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

Conditions

Pancreatic Cancer

Pancreatic Carcinoma

Pancreatic Adenocarcinoma

Pancreatic Ductal Adenocarcinoma

Pancreatic Neoplasms

Study ID

NCT06388967

Start date

Mar 15, 2023

Status verified date

Jul, 2026

Completion date

Dec 30, 2030

Anticipated

Primary completion date

Dec 30, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Histological diagnosis of pancreatic ductal adenocarcinoma, stages I-IV (TNM classification, 8th edition)
  • Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment.
  • Imaging- or endoscopy-based proof of lack of pancreatic ductal adenocarcinoma at the time of sampling (Non-disease controls)

Exclusion Criteria:

  • Lack of written informed consent.

Study Design

Enrollment

2000 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients with Pancreatic Cancer Ductal Adenocarcinoma (Training)

Individuals diagnosed with pancreatic ductal adenocarcinoma

Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Training)

Individuals without pancreatic ductal adenocarcinoma

Patients with Pancreatic Cancer Ductal Adenocarcinoma (Validation)

Individuals diagnosed with pancreatic ductal adenocarcinoma

Individuals without Pancreatic Cancer Ductal Adenocarcinoma (Validation)

Individuals without pancreatic ductal adenocarcinoma

Interventions

PANcreatic cancer Exosome Early detectiON (PANXEON)

This test will utilize quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) to quantify the expression levels of 5 cell-free and 8 exosome-miRNAs in plasma samples obtained from patients with pancreatic ductal adenocarcinoma and from individuals without it

Primary outcome measure

  • Sensitivity [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts and Locations

Central contacts

Ajay Goel, PhD

6262183452AJGOEL@COH.ORG

Locations

Translational Genomics Research Institute

Recruiting

Phoenix, Arizona, United States, 85004

Contacts

Daniel Von Hoff

dvh@tgen.org

Principal Investigator:

Daniel Von Hoff

Honorhealth

Recruiting

Scottsdale, Arizona, United States, 85258

Contacts

Erkut Borazanci

erkut.borazanci@honorhealth.com

City of Hope Medical Center

Recruiting

Monrovia, California, United States, 91016

Contacts

Ajay Goel, PhD

626-218-3452AJGOEL@COH.ORG

Principal Investigator:

Ajay Goel

Hoag Center

Recruiting

Newport Beach, California, United States, 92663

Contacts

Michael Demeure

michael.demeure@hoag.org

OSF HealthCare

Recruiting

Peoria, Illinois, United States, 61637

Contacts

Chandler Wilfong

chandler.d.wilfong@osfhealthcare.org

Ochsner Medical Center

Recruiting

Jefferson, Louisiana, United States, 70121

Contacts

John Bolton

jbolton@ochsner.org

Atlantic Health System

Recruiting

Morristown, New Jersey, United States, 07960

Contacts

Angela Alistar

angela.alistar@atlantichealth.org

Piedmont Medical Center

Recruiting

Rock Hill, South Carolina, United States, 29732

Contacts

Andrew Page

Andrew.Page@piedmont.org

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Douglas Evans

devans@mcw.edu

More Information

Sponsor

City of Hope Medical Center

Last update posted

Jul 16, 2026

Last verified

Jul, 2026

Keywords

  • Micro RNA
  • Exosome
  • Cell free
  • Early detection
  • Screening

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2026-07-16.